Global Molecular Diagnostics Point of Care Market Growth (Status and Outlook) 2023-2029

Global Molecular Diagnostics Point of Care Market Growth (Status and Outlook) 2023-2029

The global Molecular Diagnostics Point of Care market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Molecular Diagnostics Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Molecular Diagnostics Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Molecular Diagnostics Point of Care is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Molecular Diagnostics Point of Care players cover Abbott Laboratories, Abaxis, Bayer Healthcare, Bio-Rad Laboratories, Becton Dickinson and Company, Binx Health, BioMerieux, Co-Diagnostics and DanaherCorporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

The Molecular Diagnostics Point of Care enables physicians to improve the standard of care by combining rapid diagnosis with treatment decisions during the first patient visit.

LPI (LP Information)' newest research report, the “Molecular Diagnostics Point of Care Industry Forecast” looks at past sales and reviews total world Molecular Diagnostics Point of Care sales in 2022, providing a comprehensive analysis by region and market sector of projected Molecular Diagnostics Point of Care sales for 2023 through 2029. With Molecular Diagnostics Point of Care sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Molecular Diagnostics Point of Care industry.

This Insight Report provides a comprehensive analysis of the global Molecular Diagnostics Point of Care landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Molecular Diagnostics Point of Care portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Molecular Diagnostics Point of Care market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Molecular Diagnostics Point of Care and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Molecular Diagnostics Point of Care.

This report presents a comprehensive overview, market shares, and growth opportunities of Molecular Diagnostics Point of Care market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Assays and Kits
Instruments and Analyzers
Software and Services
Others

Segmentation by application
Tumor
Hematology
Endocrinology
Infectious Disease
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Abaxis
Bayer Healthcare
Bio-Rad Laboratories
Becton Dickinson and Company
Binx Health
BioMerieux
Co-Diagnostics
DanaherCorporation
Dako
F. Hoffmann
OraSure Technologies
Roche Diagnostics
Nipro Diagnostics
Genestat
Meridian Bioscience
Molbio Diagnostics
Siemens Healthcare
Thermo Fisher Scientific
Visby Medical
Wuhan Easy Diagnosis Biomedicine
Beijing Tiandz
Beijing Content

Please note: The report will take approximately 2 business days to prepare and deliver.